Paul T. Kirschmeier - Concepedia

Author

Paul T. Kirschmeier

Also Known As

P Kirschmeier, P T Kirschmeier, P. KIRSCHMEIER, P. Kirschmeier, PAUL T. KIRSCHMEIER, Paul Kirschmeier, Paul T Kirschmeier, Paul T. Kirschmeier, Roberts, Patrick J.

333

Publications

12.8K

Citations

H-Index

Concepts

All Affiliations

Dana-Farber Cancer Institute Columbia University AIL Research (United States)Brigham and Women's Hospital Merck & Co., Inc., Rahway, NJ, USA (United States)

About

Paul T. Kirschmeier is an author at Dana-Farber Cancer Institute specializing in medicine, cell biology, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	32	52	5.6K
2	Natural Sciences	18	22	1.5K
3	Biochemistry	15	17	1.4K
4	Engineering	1	1	43
5	Health Sciences	1	1	673

Paul T. Kirschmeier

Publications

12.2K

Citations

H-Index

Page 1

	Year	Citations
K- and N-Ras Are Geranylgeranylated in Cells Treated with Farnesyl Protein Transferase Inhibitors David B. Whyte, Paul T. Kirschmeier, Tish Hockenberry, Journal of Biological Chemistry	1997	872
Noninvasive Detection of Response and Resistance in <i>EGFR</i> -Mutant Lung Cancer Using Quantitative Next-Generation Genotyping of Cell-Free Plasma DNA Geoffrey R. Oxnard, Cloud P. Paweletz, Yanan Kuang, Clinical Cancer Research	2014	772
Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors Erick J. Morris, Sharda Jha, Clifford R. Restaino, Cancer Discovery PharmacotherapyTumor BiologyDrug ResistanceMek InhibitorsReceptor Tyrosine Kinase	2013	673
Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor David Parry, Timothy J. Guzi, Nicole R. Davis, Molecular Cancer Therapeutics PharmacotherapyCancer BiologyTumor BiologyCdk9 ActivityReceptor Tyrosine Kinase	2010	553
<i>Ex Vivo</i> Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids Russell W. Jenkins, Amir Reza Aref, Patrick H. Lizotte, Cancer Discovery	2017	552
Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway Asra Mirza, Marnie McGuirk, Tish Hockenberry, Oncogene Tumor BiologyWild-type P53P53-dependent Apoptotic PathwayPathologyTumor Suppressor	2002	534
Suppression of STING Associated with LKB1 Loss in KRAS-Driven Lung Cancer Shunsuke Kitajima, Elena V. Ivanova, Sujuan Guo, Cancer Discovery	2018	489
Overproduction of protein kinase C causesdisordered growth control in rat fibroblasts Gerard M. Housey, Mark D. Johnson, W.L. Wendy Hsiao, Cell Rat FibroblastsFibrosisDevelopmental BiologySignal TransductionProtein Kinase C	1988	488
Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway Kari J. Kurppa, Yao Liu, Ciric To, Cancer Cell Tumor BiologySignaling PathwayCell RegulationMedicineTreatment-induced Tumor Dormancy	2020	454
Rho Family GTPase Modification and Dependence on CAAX Motif-signaled Posttranslational Modification Patrick J. Roberts, Natalia Mitin, Patricia J. Keller, Journal of Biological Chemistry	2008	341

Page 1